N/A N=39 Transcranial Magnetic Stimulation for Adolescent Depression
Major Depressive Disorder
Primary: Hamilton Depression Rating Scale — 9.38 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=42 OTR Tablet 40 mg Fed-state Bioequivalence Study
Chronic Pain
Primary: Cmax of OTR Tablet 40 mg and OXYCONTIN Tablet 40 mg in a Fed State — 86.15; 63.54 ng/ml
N/A N=36 Preoperative Olaparib Endometrial Carcinoma Study (POLEN)
Endometrial Carcinoma
Primary: Expression of Cell Cycle-related Proteins — 46.1; 0.8; 0.7 score on a scale — p=0.033
N/A N=703 Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients
Acute Myeloid Leukemia (AML) · Myelodysplastic Syndrome (MDS)
Primary: Percentage Analyzed Participants Receiving Hematopoietic Stem Cell Transplantation (HCT) — 44.7 % participants
Phase 3 N=50 Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Acne Vulgaris
Primary: Subject 's Overall Satisfaction With Study Treatment Via a Satisfaction Questionnaire — 36 Participants
N/A N=55 The General Use of Robots in Stroke Recovery: the Anklebot
Stroke
Primary: Mean Change From Baseline in Gait Speed (m/Sec) on the 10 Meter Walk Test at Comfortable Pace. — 0.22; 0.53; 1.02; 0.26 m/sec — p=<0.001
Phase 4 N=67 Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Acne Vulgaris · Atrophic Acne Scars
Primary: Part 1: Total Atrophic Acne Scar Count Per Half-face — 9.5; 13.3 atrophic acne scars — p=<0.0001
Phase 4 N=58 Tobacco and Socioeconomic Disadvantage
Tobacco Smoking
Primary: Self-reported Serious Quit Attempt Measured Via the 'Quitting Preparation and Actions Questionnaire' — 5; 10; 6 Participants — p=<0.05
N/A N=141 Build Better Bones With Exercise
Osteoporotic Fractures · Spinal Fractures
Primary: Feasibility of Recruitment and Retention — 66; 64 Participants
N/A N=16 Medtronic Minimed Overnight Closed-Loop System
Type 1 Diabetes Mellitus · Autoimmune Diabetes · Juvenile-Onset Diabetes
Primary: Target Sensor Glucose 70-150 mg/dl — 66.4; 50.6 percentage of time — p=0.004
Phase 2 N=47 A Multiple Dose Opioid Challenge Study
Moderate or Severe Opioid Use Disorder
Primary: Treatment Phase Drug Liking Visual Analog Scale (VAS) Emax Scores for Baseline and Four Challenge Sessions Compared to Baseline (Completer Population) for CAM2038 q1w…
Phase 2 N=207 Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
Adjunctive Treatment of Major Depressive Disorder
Primary: Change From Baseline to Week 5 in the HAMD-17 Total Score — 22.9; 22.0; 20.3; 20.4 score on a scale — p=0.0390
Phase 2 N=32 Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease, COPD
Primary: Peak Forced Expiratory Volume in One Second (FEV1) Relative to Baseline — 1708.0; 1877.3; 1881.8; 1883.6 mL — p=<0.001
Phase 1 N=16 A Study of the Use of Microneedle Patches to Deliver Topical Lidocaine in the Oral Cavity
Topical Anaesthesia
Primary: VAS in Healthy Participants, When Topical 5% Lidocaine Dental Gel Was Applied to the Upper Palatal and Upper Anterior Buccal Sulcus Areas With a Microneedle Patch and a…
Phase 2 N=15 Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
Type 1 Diabetes Mellitus
Primary: Effect of Anakinra Treatment on PBMC Gene Expression for Patients — 0 probe sets